Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma

Abstract

Background: Accurate clinical staging of patients with cholangiocarcinoma (CCA) has a significant impact on treatment decisions. In this study, we aimed to compare the diagnostic value of magnetic resonance imaging (MRI) and 18-fludeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) for staging of CCA. Methods: We performed comprehensive systematic search in Web of Science (including MEDLINE) and Excerpta Medica Database for relevant diagnostic studies in accordance with the preferred reporting items for systematic reviews and meta-analysis statement. Based on data extracted from patient-based analysis, we calculated the pooled sensitivity and specificity with the 95% confidence intervals (CIs). In addition, the publication bias was assessed by Deek funnel plot of the asymmetry test. The potential heterogeneity was explored by threshold effect analysis and subgroup analyses. Results: Thirty-two studies with 1626 patients were included in present analysis. In T stage, the pooled sensitivity and specificity of MRI were 0.90 (95% CI 0.86–0.93), 0.84 (95% CI 0.73–0.91) respectively. The pooled sensitivity and specificity of 18 F-FDG PET/CT were 0.91 (95% CI 0.83–0.95) and 0.85 (0.64–0.95) respectively. In N stage, the pooled sensitivity and specificity of MRI were 0.64 (95% CI 0.52–0.74) and 0.69 (95% CI 0.51–0.87) respectively. The pooled sensitivity and specificity of PET/CT were 0.52 (95% CI 0.37–0.66) and 0.92 (95% CI 0.79–0.97) respectively. In M stage, the pooled sensitivity and specificity of 18 F-FDG PET/CT were 0.56 (95% CI, 0.42–0.69) and 0.95 (95% CI, 0.91–0.97) respectively. The Deek test revealed no significant publication bias. No threshold effect was identified. The subgroup analyses showed that pathological type (extrahepatic cholangiocarcinoma vs hilar cholangiocarcinoma/intrahepatic cholangiocarcinoma), country (Asia vs non-Asia) and type of MRI (1.5T vs. 3.0T) were potential causes for the heterogeneity of MRI studies and country (Asia vs non-Asia) was a potential source for 18 F-FDG PET/CT studies. Conclusion: The analysis suggested that both modalities provide reasonable diagnostic accuracy in T stage without significant differences between them. We recommend that both modalities be considered based on local availability and practice for the diagnosis of primary CCA tumors. In N stage, the diagnosis of lymph node metastasis (N) of CCA is still limited by MRI and 18 F-FDG PET/CT, due to unsatisfactory diagnostic accuracy of both. Nevertheless, 18 F-FDG PET/CT can be used to confirm lymph node metastasis while a negative result may not rule out metastasis. Furthermore, 18 F-FDG PET/CT have a low sensitivity and a high specificity for detection of distant metastas...

Multimodal magnetic resonance imaging for the diagnosis of parotid gland malignancies: systematic review and meta-analysis

“…At present, there is still a lack of unified guidelines for the assessment of benign and malignant parotid tumors before surgery. Most clinicians can diagnose them solely on personal clinical experience (18). This is more subjective and uncertain in empirical medicine, which may cause misdiagnosis and affect the treatment and prognosis of patients.…”

Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies

“…A recent meta-analysis, comparing 18 F-FDG PET/CT and MR in staging iCCA, found no significant difference in primary tumor detection, though PET offered improved detection of nodal metastatic disease. 20 In addition to staging utility, 18 F-FDG PET/CT after radioembolization documents radioembolic distribution and, thus, tumor coverage (►Fig. 1).…”

Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies

“…However, data regarding regional node metastasis and N stage are limited owing to the unsatisfactory diagnostic accuracy of both imaging modalities. Furthermore, [ 18 F]FDG PET/CT has low sensitivity but high specificity for detecting distant metastasis, with reported pooled sensitivity and specificity of 56% and 95%, respectively [ 8 ]. Gallium (Ga)68-labelled fibroblast activating protein inhibitor (FAPI) was developed to evaluate fibroblast activation in oncological imaging, with fibroblast activating proteins being highly expressed in cancer-associated fibroblasts in various epithelial carcinomas.…”